<DOC>
	<DOCNO>NCT01640080</DOCNO>
	<brief_summary>The purpose study assess efficacy esketamine compare placebo improve symptom depression patient treatment resistant depression .</brief_summary>
	<brief_title>A Study Efficacy Intravenous Esketamine Adult Patients With Treatment-Resistant Depression</brief_title>
	<detailed_description>This double-blind ( neither physician patient know treatment patient receives ) , double-randomization ( study drug assign chance ) , placebo-controlled ( placebo inactive substance compare drug test whether drug real effect clinical trial ) , multiple dose titration study adult patient treatment resistant depression ( TRD ) . The study ass efficacy esketamine 24 hour dose Day 1 , administer 0.40 mg/kg 0.20 mg/kg intravenous ( i.v . ) infusion , compare placebo improve symptom depression patient TRD , use Montgomery-Asberg Depression Rating Scale ( MADRS ) . The study consist 3 phase : screen phase 2 week , 7-day double-blind treatment phase ( Day 1 Day 7 ) , 4-week posttreatment ( follow ) phase . The interval first last dose study medication 3 day . The total study duration patient maximum 7 week .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<criteria>Be medically stable basis clinical laboratory test Diagnostic major depressive disorder ( MDD ) without psychotic feature Have inadequate response least 1 antidepressant current episode depression least one inadequate treatment response antidepressant either current episode previous episode Women must pregnant ; woman must postmenopausal , surgically sterile , heterosexually active , practice highly effective method birth control study 3 month receive last dose study drug Men must agree use double barrier method birth control donate sperm study 3 month receive last dose study drug Signed inform consent document History , current sign symptoms disease condition would make participation best interest ( eg , compromise wellbeing ) patient could prevent , limit , confound protocolspecified assessment Has uncontrolled hypertension ( systolic blood pressure ( SBP ) &gt; 160 mmHg diastolic blood pressure ( DBP ) &gt; 90 mmHg despite diet , exercise stable dose allow antihypertensive treatment ) past history hypertensive crisis Has know human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C infection , positive result screen Has primary diagnosis current ( active ) generalize anxiety disorder , panic disorder , obsessive compulsive disorder , posttraumatic stress disorder , anorexia nervosa , bulimia nervosa Has history current diagnosis psychotic disorder , bipolar disorder , mental retardation , borderline personality disorder , mood disorder postpartum onset , somatoform disorder chronic fatigue syndrome Has major surgery , ( eg , require general local anesthesia ) within 4 week screen , fully recover surgery , plan surgery time subject expect participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Major depressive disorder</keyword>
	<keyword>Treatment resistant depression</keyword>
	<keyword>Depression</keyword>
	<keyword>Esketamine</keyword>
</DOC>